All4Cure

What All4Cure does

All4Cure is a Seattle-based digital health platform focused exclusively on multiple myeloma that connects patients, clinicians, and researchers through a collaborative knowledge-sharing ecosystem. The company aggregates patient medical records across institutions, uses trained professionals to extract critical labs and treatment history, and presents the information via personalized dashboards alongside real-world outcomes comparisons and clinical trial matching. Participation is free for patients, and the platform is designed to enable general oncologists to deliver expert-level myeloma care through expert case review, decision support, and cooperative learning. The company serves multiple myeloma patients, hematologists and oncologists, cancer researchers, and community oncology practices, with reported scale of 1,000+ enrolled patients, 400+ clinicians and researchers, and 584 participating oncology clinics and cancer care centers.

The core product suite includes the All4Cure Patient Dashboard, the Value-Based Clinical Pathway for Multiple Myeloma, MyelomaMap Reports (real-world outcomes data focused on relapsed refractory myeloma), PRO surveys, a community forum, and clinical trial matching services. Sub-brands include MyelomaMap, the Value-Based Clinical Pathway, and the Pod4Cure podcast. Distribution combines direct patient self-service enrollment with channel partnerships such as OnCare for community oncology deployment and Exigent Research for clinical trial matching. Recent strategic moves include the April 2024 OnCare partnership, the August 2025 Exigent Research partnership, MyelomaMap and clinical pathway product launches, and a 2025 Prix Galien USA nomination for Best Digital Health Solution.

The business model is currently freemium for patients, with Terms of Service indicating that some future features may require fees; no pricing tiers or enterprise contract values are disclosed, and no venture funding rounds are documented. The company is led by Founder and CEO Dr. C. Anthony Blau with a small disclosed executive team including a VP of Operations. Commercial revenue, if any, is most plausibly tied to partnership arrangements and future paid features rather than patient subscriptions.

Name

All4Cure

Legal name

All4Cure, Inc.

Website

https://all4cure.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

All4Cure is a digital health platform connecting multiple myeloma patients, clinicians, and researchers through a collaborative ecosystem. It offers free patient enrollment, treatment dashboards, real-world outcomes data, clinical trial matching, and expert case review to optimize cancer care.

Ownership category

akta.pro rank

Product category

Oncology Digital Health Platform

NAICS

Computer Systems Design Services (541512), Computer Systems Design and Related Services (54151)

SIC

Services-Health Services (8000), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

akta.pro secondary industries

Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), FHIR/HL7 Data Repositories & Canonical Data Models (HLACAIAI)

Keywords

• Multiple myeloma platform
• Clinical decision support
• Patient-reported outcomes
• Real-world evidence oncology
• Clinical trial matching

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Free Patient Platform: Platform participation is free for all patients. The company appears to be in early-stage growth mode, building network effects before monetizing.
2. Future Paid Features: Terms of Service indicate that certain future features of the Service may require payment of fees. All fees are stated to be in U.S. Dollars and non-refundable.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

All4Cure operates a digital health platform that unifies real-time patient data, analytics, expert decision support, and dashboards into a single treatment optimization ecosystem for multiple myeloma. The company provides a free patient-facing dashboard with treatment history visualization, expert-reviewed case insights, and clinical trial matching, plus clinician-facing tools such as the Value-Based Clinical Pathway for Multiple Myeloma and MyelomaMap real-world outcomes reports.

Product overview

All4Cure is a digital health platform designed as a unified ecosystem for multiple myeloma care, connecting patients, clinicians, and researchers. The platform consists of a patient-facing dashboard for health tracking and treatment visualization, the Value-Based Clinical Pathway for evidence-based treatment guidance, MyelomaMap reports drawing from real-world data outcomes, PRO surveys for patient-reported outcomes, a community forum for peer support, and clinical trial matching services. Participation is free for patients, and the platform emphasizes secure, anonymous data sharing with expert review of cases.

Differentiator

Problem solved

Functional benefit

Brands

• MyelomaMap: Real-world database reports for relapsed refractory multiple myeloma (RRMM) patient treatment review and outcomes comparison.
• Value-Based Clinical Pathway for Multiple Myeloma
• Pod4Cure

Products and services

• All4Cure Patient Dashboard A personalized dashboard that provides multiple myeloma patients with graphical and narrative summaries of their cancer experience, full treatment history visualization, and access to clinical trial matching. Patient enrollment is free, anonymous, and HIPAA-compliant.
• Value-Based Clinical Pathway for Multiple Myeloma An evidence-based clinical pathway resource for clinicians and patients that provides treatment suggestions for newly diagnosed multiple myeloma patients, updated as new data becomes available. Developed in partnership with OnCare community oncology network.
• MyelomaMap Reports Real-world database reports that enable clinicians and patients to review treatment choices and outcomes of similar patients, particularly for relapsed refractory multiple myeloma (RRMM), to inform treatment strategies.
• PRO Survey Patient-reported outcome surveys that enable multiple myeloma patients to share health experiences and quality-of-life data, contributing to treatment insights and clinical research.
• Community Forum An online community forum where multiple myeloma patients, caregivers, clinicians, and researchers share experiences, discuss treatments, and support one another through the myeloma journey.
• Clinical Trial Matching A service that evaluates patient diagnosis, treatment history, and medical records to pre-screen and match multiple myeloma patients with eligible clinical trials, facilitating connections between patients and trial sponsors.

Quantifiable outcome

• 1,000+ myeloma patients enrolled on platform
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Exigent ResearchcoreStrategic or Co-development Partner · 6 August 2025Master Services Agreement (MSA) with Exigent Research, a multi-site clinical trials research organization based in Tacoma, Washington. Currently collaborating on three projects: two clinical trial matching programs to help patients find trials tailored to their unique needs, and a clinical trial exploring a new hematology assay. The partnership aims to make cutting edge clinical trials available to patients where they live and bridge critical gaps between patients, medical teams, and researchers.
• OnCarecoreStrategic or Co-development Partner · 16 April 2024Partnership with OnCare, a network of community oncology practices dedicated to advancing patient-centric care, to build and release the Value-Based Clinical Pathway for Multiple Myeloma. The pathway empowers both clinicians and patients to make informed decisions about myeloma care based on principles of achieving MRD negativity, prioritizing clinical trial enrollment, and sequencing treatments to minimize toxicities.
• Dana-Farber Cancer InstituteminorStrategic or Co-development PartnerDr. Ken Anderson from Dana-Farber Cancer Institute in Boston, MA is featured as a supporter, providing a testimonial endorsement: 'All4Cure provides an amazing innovative resource to patients and caregivers to assure that they can receive the most current promising therapies.'

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Foundation Medicine: Roche subsidiary providing comprehensive genomic profiling and a large molecular data warehouse used by oncologists and pharma; comparable as a broad incumbent in oncology data-driven decision support and pharma partnerships.
• Tempus Labs: Precision medicine platform combining molecular profiling, real-world evidence, and AI tools for oncology clinicians; comparable to All4Cure's data-driven decision support and trial-matching thesis, but with multi-indication breadth and significant pharma partnerships.
• Medidata (Dassault Systèmes): Clinical trial technology platform with deep pharma and site relationships for trial design and patient recruitment; comparable to All4Cure's trial-matching capability, but at vastly larger scale across all therapeutic areas.
• Flatiron Health: Roche-owned oncology real-world data and EHR company; directly comparable to All4Cure's MyelomaMap-style outcomes aggregation and clinical-trial matching, but operates across all oncology at much larger scale.

Direct peers

• COTA Healthcare: Real-world oncology data and analytics company curating EHR data to support care decisions and pharma research; closely mirrors All4Cure's real-world evidence and decision-support positioning in oncology.
• Syapse: Precision oncology platform that aggregates real-world data across health systems to support clinical decision making and pharma partnerships; overlaps All4Cure's data integration, decision support, and pharma-data-licensing model.
• Navigating Cancer: Patient and clinician-facing oncology platform with symptom tracking, care plans, and patient engagement tools; directly comparable to All4Cure's patient dashboard and clinician network model in community oncology.

Emerging players

• CancerIQ: Precision cancer prevention and early-detection platform used by community health systems; adjacent peer sharing All4Cure's community oncology distribution and clinical pathway enablement.
• Outcomes4Me: Patient-centric cancer platform offering treatment guidance, clinical trial matching, and personalized insights; comparable to All4Cure's patient dashboard and trial-matching functionality, though not indication-specific.
• Antidote Technologies: Digital clinical-trial recruitment platform that matches patients to trials across multiple conditions; comparable as an emerging player in oncology trial matching and patient engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/All4Cure
• YouTubeyoutube.com/@all4cure50
• Facebookfacebook.com/all4cure
• Instagraminstagram.com/all4cure

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about All4Cure